BNTX ▼ -1.2% - BioNTech SE $BNTX - BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer 13-OCT-2026 06:45 AM ET